Calidi prices 1.47M units at $2.00 in underwritten public offering

Calidi (CLDI) Biotherapeutics announced the pricing of an underwritten public offering for gross proceeds of $6M prior to deducting underwriting commissions and offering expenses. The offering is comprised of 1,472,764 common stock units with each unit consisting of one share of common stock and one Series I warrant to purchase one share of common stock and 1,528,000 pre-funded warrant units consisting of one pre-funded warrant to purchase one share of common stock and one Series I warrant to purchase one share of common stock. The price per Common Stock Unit is $2.00 and the price per Pre-Funded Unit is $1.999. The Series I warrant will have an exercise price of $2.00 per share, will be exercisable upon issuance, and have a term expiring five years from issuance. The warrants issued in this offering are fixed priced and do not contain any variable price features. Ladenburg Thalmann & Co. is acting as sole book-running manager for the offering. Laidlaw & Company is acting as a co-manager for the offering. In addition, Calidi has granted the underwriters a 45-day option to purchase up to an additional 450,000 shares of common stock and/or warrants, at the public offering price, less underwriting discounts and commissions. This offering is expected to close on or about August 21, 2025, subject to the satisfaction of customary closing conditions.